Pinealon Evidence Guide
Evidence for Pinealon is too preliminary to support a research protocol with confidence. All data originates from a single Russian research group (Khavinson et al.) with no independent replication by Western or Asian research programs. The regulatory context and peer review standards differ substantially. Of the Cognitive & Nootropic compounds in this library, cerebrolysin has far more RCT data from independent groups.
Our Take
Evidence for Pinealon is too preliminary to support a research protocol with confidence. All data originates from a single Russian research group (Khavinson et al.) with no independent replication by Western or Asian research programs. The regulatory context and peer review standards differ substantially. Of the Cognitive & Nootropic compounds in this library, cerebrolysin has far more RCT data from independent groups.
- Evidence context
- Neuroprotective peptide research (Russian data only)
- Evidence grade
- Level D
- Confidence
- Low
- Reference context
- Reported research reference: No established human protocol outside Russian clinical context
Benefits and Evidence
- Neuroprotection Under Hypoxia: Level D, mostly non-human evidence - Khavinson et al. (2011, Bull Exp Biol Med) demonstrated Pinealon (Glu-Asp-Arg) at 10-100 nM protected rat cortical neurons from hypoxia-induced apoptosis, increasing superoxide dismutase activity by 40% and reducing ROS production by 35% in oxygen-glucose deprivation models.
- Memory and Learning: Level D, mostly non-human evidence - Aged rodents treated with Pinealon demonstrated improved performance in maze-based learning tasks and enhanced long-term memory consolidation compared to controls.
- Circadian Rhythm Regulation: Level D, mostly non-human evidence - Preliminary evidence suggests Pinealon may modulate melatonin output from pineal gland cells in culture, potentially supporting circadian rhythm normalization.
Side Effects and Warnings
- Mild drowsiness
- Headache (rare)
- Vivid dreams
- Research is almost exclusively from Russian institutions with limited independent replication
- No human clinical trials have been conducted
- Long-term safety profile is unknown
Research Dosage References
- <strong>Sublingual</strong> - 100-500 mcg - Once or twice daily - Sublingual administration is preferred to bypass first-pass metabolism. No standardized human dosing exists.
- <strong>Intranasal</strong> - 100-300 mcg - Once daily - Intranasal delivery may improve CNS bioavailability. Experimental only.
Mechanism of Action
Pinealon penetrates cell membranes and nuclear envelopes due to its small size and specific amino acid composition. It interacts with histone proteins and DNA regulatory regions to modulate transcription of genes involved in antioxidant defense (SOD, catalase), anti-apoptotic signaling (Bcl-2), and synaptic plasticity (BDNF, CREB). It also appears to regulate melatonin synthesis in the pineal gland by influencing tryptophan hydroxylase expression.
Legal Status
Unregulated research peptide in most countries; available as a supplement in Russia.
Primary Sources
- Neuroprotective effects of short peptides in the context of oxidative stress. Bulletin of Experimental Biology and Medicine, 2016.
- Short peptides and the regulation of gene expression in aging brain cortex. Advances in Gerontology, 2014.
Quick Answers
Where is the strongest evidence for Pinealon?
Evidence for Pinealon is too preliminary to support a research protocol with confidence. All data originates from a single Russian research group (Khavinson et al.) with no independent replication by Western or Asian research programs. The regulatory context and peer review standards differ substantially. Of the Cognitive & Nootropic compounds in this library, cerebrolysin has far more RCT data from independent groups. Evidence context: Neuroprotective peptide research (Russian data only).
What are the main side effects of Pinealon?
Pinealon side effects and warning signals include Mild drowsiness, Headache (rare), Vivid dreams, Research is almost exclusively from Russian institutions with limited independent replication, and No human clinical trials have been conducted.
What evidence level is Pinealon?
Pinealon is rated Level D; the listed research status is Early Research.